期刊
PSYCHOPHARMACOLOGY
卷 212, 期 3, 页码 301-307出版社
SPRINGER
DOI: 10.1007/s00213-010-1956-y
关键词
Schizophrenia; Smoking; Nicotine; Brain-derived neurotrophic factor; Neurotrophin
资金
- Stanley Medical Research Institute [03T-459, 05T-726]
- Department of Veterans Affairs
- US National Institute of Health [K05-DA0454, P50-DA18827, U01-MH79639]
- VISN 16, Mental Illness Research, Education and Clinical Center (MIRECC)
Schizophrenia is associated with a significantly high prevalence of smoking. Upregulation of neurotrophins by nicotine is well established. Accumulating evidence shows that brain-derived neurotrophic factor (BDNF) may be involved in the pathophysiology of schizophrenia. The purposes of this study were to compare BDNF levels in smokers to nonsmokers with schizophrenia and examine the association between BDNF levels and psychopathological symptoms. Serum BDNF levels were measured in 139 male inpatients with DSM-IV schizophrenia: 102 smokers and 37 nonsmokers. Symptoms were assessed with the Positive and Negative Syndrome Scale (PANSS). The positive PANSS symptoms were lower in smokers than in nonsmokers, while the negative symptoms were lower in those who smoked more cigarettes. BDNF levels were significantly higher in smokers than in nonsmokers (p < 0.05). Higher BDNF levels correlated with fewer negative symptoms and with smoking more cigarettes. The fewer positive symptoms in smokers and fewer negative symptoms in those who smoked more cigarettes may be associated with nicotine-induced upregulation of BDNF.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据